CCM
SRPT icon

CTC Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

CTC Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$758K Buy
5,500
+3,100
+129% +$402K 1.59% 23
2022
Q4 		$311K Buy
+2,400
New +$278K 0.36% 65

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CTC Capital Management's SRPT Position: Q1 2023 in Review

CTC Capital Management increased its Sarepta Therapeutics (SRPT) stake by 129% in Q1 2023, buying an estimated $402K and bringing the position to 5,500 shares worth $758K. The position accounts for 1.59% of the portfolio, ranked #23.

CTC Capital Management first reported a position in SRPT in Q4 2022 and has held it in 2 quarters since. 425 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

  • CTC Capital Management held 5,500 shares of Sarepta Therapeutics worth $758K as of Q1 2023.
  • CTC Capital Management bought 3,100 Sarepta Therapeutics shares in Q1 2023, an estimated $402K.
  • Sarepta Therapeutics made up 1.59% of CTC Capital Management's portfolio in Q1 2023, its #23 holding.
  • CTC Capital Management first reported a position in Sarepta Therapeutics in Q4 2022 and has held it in 2 quarters since.
  • 425 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on CTC Capital Management's 13F filing for Q1 2023, filed 5 May 2023.